维迪西妥单抗联合替雷利珠单抗治疗经尿道不可切除的ERBB2阳性高危非肌层浸润性膀胱癌:非随机临床试验
这项开放标签、单臂、2期非随机临床试验评估了维迪西妥单抗联合替雷利珠单抗在经尿道不可切除的ERBB2阳性极高危非肌层浸润性膀胱癌患者中的疗效与安全性。26例可评估患者的高危疾病完全缓解率为73.1%(95%CI 54.8%-91.3%),达到预设70%的替代率目标;中位随访29.4个月,应答者24个月持续应答率83.5%,未发生肌层浸润或转移进展。治疗相关不良事件发生率89.3%,最常见为感觉异常、脱发和瘙痒,4例(14.3%)发生3-4级事件。
要点
- DV联合替雷利珠单抗在经尿道不可切除ERBB2阳性VHR NMIBC中完全缓解率达73.1%。
- 应答者24个月持续应答率83.5%,无肌层浸润或转移进展。
- 3-4级治疗相关不良事件发生率14.3%,无5级事件。
核心结论
- 维迪西妥单抗联合替雷利珠单抗在经尿道不可切除的ERBB2阳性极高危非肌层浸润性膀胱癌中显示出较高的完全缓解率和持久的疾病控制,支持开展随机临床试验。
研究设计与样本
- 开放标签、单臂、2期非随机临床试验,采用Simon两阶段设计,于2022年8月至2024年5月在学术医院开展,中位随访29.4个月。
- 筛查137例患者,纳入28例经尿道不可切除、符合2019年欧洲泌尿外科学会极高危标准且不适合或拒绝膀胱切除术的ERBB2阳性NMIBC成人患者。
- 全治疗分析中2例预评估退出计为非应答者,26例可进行疗效评估。
主要发现
- 26例可评估患者中19例达到高危疾病完全缓解,完全缓解率73.1%(95%CI 54.8%-91.3%),达到预设70%的替代率目标。
- 全部28例中19例应答,应答率67.9%(95%CI 49.4%-86.3%),超过17例应答的精确二项阈值。
- 应答者24个月持续应答率为83.5%(95%CI 68.0%-100.0%),未发生肌层浸润或转移进展。
- 治疗相关不良事件发生于25例(89.3%),最常见为感觉异常12例(42.9%)、脱发11例(39.3%)、瘙痒10例(35.7%);4例(14.3%)发生3-4级事件,2例(7.1%)因不良事件停药,无5级事件。
关键数值与推荐
- 完全缓解定义为无高级别肿瘤、T1期疾病、原位癌或进展。
- 给药方案为维迪西妥单抗120 mg第1天联合替雷利珠单抗200 mg第2天,每3周一次,共3个周期;应答者最多接受8个周期维迪西妥单抗和17个周期替雷利珠单抗。
临床怎么用
- 对于经尿道不可切除、ERBB2阳性且不适合或拒绝膀胱切除术的极高危NMIBC患者,维迪西妥单抗联合替雷利珠单抗可作为潜在的非手术治疗选择。
- 治疗期间需关注感觉异常、脱发、瘙痒等治疗相关不良事件,并监测3-4级毒性。
局限性
- 单臂、非随机设计,样本量较小,结论需随机临床试验进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Very high-risk non-muscle-invasive bladder cancer (VHR NMIBC) includes extensive high-grade T1 (T1HG) disease, T1HG with carcinoma in situ, variant histology, lymphovascular invasion, or bacille Calmette-Guérin (BCG)-unresponsive disease. Transurethrally unresectable disease warrants radical cystectomy, but patients ineligible for or declining cystectomy lack established nonsurgical therapy. OBJECTIVE: To evaluate the efficacy and safety of disitamab vedotin (DV, an anti-ERBB2 [formerly HER2] antibody-drug conjugate) plus tislelizumab (an anti-programmed cell death 1 protein immune checkpoint inhibitor) in transurethrally unresectable ERBB2-positive VHR NMIBC. DESIGN, SETTING, AND PARTICIPANTS: This was an open-label, single-arm, phase 2, nonrandomized clinical trial with a Simon 2-stage design, conducted in an academic hospital from August 2022 to May 2024 with a median follow-up of 29.4 months. The analysis included adults with transurethrally unresectable ERBB2-positive NMIBC who met the 2019 European Association of Urology VHR criteria and who were ineligible for or declined cystectomy. INTERVENTION: Patients received an intravenous injection of DV (120 mg, day 1) plus tislelizumab (200 mg, day 2) every 3 weeks for 3 cycles; patients who responded received up to 8 DV cycles and 17 tislelizumab cycles. MAIN OUTCOMES AND MEASURES: The primary outcome was complete response (CR) of high-risk disease, defined as no high-grade tumor, T1 disease, carcinoma in situ, or progression. Secondary outcomes were response duration, progression-free survival, overall survival, and safety. RESULTS: Among 137 screened patients, 28 participants (median [IQR] age, 72 [67-74] years; 25 male [89%]) were included. Two preassessment withdrawals were counted as nonresponders in the all-treated analysis, which left 26 efficacy-evaluable patients. CR of high-risk disease was achieved in 19 of 26 (73.1%; 95% CI, 54.8%-91.3%), meeting the prespecified 70% alternative-rate goal. Among all 28, 19 responded (67.9%; 95% CI, 49.4%-86.3%), exceeding the 17-response exact binomial threshold. Both analyses met the primary criterion. Among responders, the 24-month sustained response was 83.5% (95% CI, 68.0%-100.0%), and no muscle invasive or metastatic progression occurred. Treatment-related adverse events occurred in 25 patients (89.3%), most commonly paresthesia (12 [42.9%]), alopecia (11 [39.3%]), and pruritus (10 [35.7%]); 4 (14.3%) had grade 3 to 4 events; 2 (7.1%) discontinued treatment; and none had grade 5 events. CONCLUSIONS AND RELEVANCE: Findings of this nonrandomized clinical trial suggest that DV plus tislelizumab may show a high CR rate and durable disease control in patients with transurethrally unresectable ERBB2-positive VHR NMIBC, supporting randomized clinical trials. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05495724.
引用
- Qie Y, Jia K, Huang S, et al. Disitamab Vedotin Plus Tislelizumab in Transurethrally Unresectable, ERBB2-Positive, Non-Muscle-Invasive Bladder Cancer: A Nonrandomized Clinical Trial. JAMA Oncol. 2026. PMID: 42848391. doi:10.1001/jamaoncol.2026.3909
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。